Diabetes-related adduct formation and retinopathy

Journal of Ocular Biology, Diseases, and Informatics

Volumn 4, Issue 1-2, 2011, Pages 10-18

  Stitt, Alan W ^a   Curtis, Timothy M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Advanced glycation; Diabetic retinopathy; Lipoxidation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED LIPOXIDATION END PRODUCT; AGENTS ACTING ON THE EYE; ALDEHYDE DEHYDROGENASE; AMINOGUANIDINE; BENFOTIAMINE; DIHYDRALAZINE; HYDRALAZINE; LACTOYLGLUTATHIONE LYASE; LIPID; LR 90; MALONALDEHYDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PYRIDORIN; PYRIDOXAMINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; INFLAMMATION; LIPID PEROXIDATION; MUELLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RETINA CAPILLARY; RETINA DEGENERATION; REVIEW;

EID: 84863988445     PISSN: 19368437     EISSN: 19368445     Source Type: Journal    
DOI: 10.1007/s12177-011-9070-x     Document Type: Review

References (91)

1. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
2. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care. 1998;21:143-56. (Pubitemid 28030402)
3. Aldini G, Dalle-Donne I, Facino RM, et al. Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med Res Rev. 2007;27:817-68. (Pubitemid 350035121)
4. Antonetti DA, Barber AJ, Bronson SK, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55:2401-11. (Pubitemid 44871140)
5. Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Investig Ophthalmol Vis Sci. 2005;46:2916-24. (Pubitemid 43086714)
6. Bhatwadekar A, Glenn JV, Figarola JL, et al. A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br J Ophthalmol. 2008;92:545-7. (Pubitemid 351497988)
7. Biedermann B, Skatchkov SN, Brunk I, et al. Spermine/spermidine is expressed by retinal glial (Muller) cells and controls distinct K+ channels of their membrane. Glia. 1998;23:209-20. (Pubitemid 28259719)
8. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 2004;24:32-40. (Pubitemid 38250484)
9. Bringmann A, Uckermann O, Pannicke T, et al. Neuronal versus glial cell swelling in the ischaemic retina. Acta Ophthalmol Scand. 2005;83:528-38. (Pubitemid 41488624)
10. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20. (Pubitemid 34000785)
11. Brownlee M, Vlassara H, Kooney A, et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986;232:1629-32. (Pubitemid 16095602)
12. Burcham PC, Fontaine FR, Kaminskas LM, et al. Protein adducttrapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity. Mol Pharmacol. 2004;65:655-64. (Pubitemid 38264033)
13. Burcham PC, Kaminskas LM, Fontaine FR, et al. Aldehydesequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology. 2002;181-182:229-36. (Pubitemid 36015704)
14. Burcham PC, Raso A, Thompson CA. Toxicity of smoke extracts towards A549 lung cells: role of acrolein and suppression by carbonyl scavengers. Chem Biol Interact. 2010;183:416-24.
15. Canning P, Glenn JV, Hsu DK, et al. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res. 2007;2007:51837.
16. Chen BH, Jiang DY, Tang LS. Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes. Life Sci. 2006;79:1040-8.
17. Chibber R, Molinatti PA, Rosatto N, et al. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia. 1997;40:156-64. (Pubitemid 27060287)
18. Curtis TM, Hamilton R, Yong PH, et al. Muller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation endproducts. Diabetologia. 2011;54:690-8.
19. No authors listed. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1993;46:271-286
20. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33:637-68. (Pubitemid 32520962)
21. Druey J, Marxer A. Hypotensive hydrazinophthalazines and related compounds. J med pharm chem. 1959;1:1-21.
22. Fosmark DS, Bragadottir R, Stene-Johansen I, et al. Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study. Acta Ophthalmol Scand. 2007;6:618-22. (Pubitemid 47316760)
23. Fosmark DS, Torjesen PA, Kilhovd BK, et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism. 2006;55:232-6. (Pubitemid 43098992)
24. Furuhata A, Nakamura M, Osawa T, et al. Thiolation of proteinbound carcinogenic aldehyde. An electrophilic acrolein-lysine adduct that covalently binds to thiols. J Biol Chem. 2002;277:27919-26. (Pubitemid 34966739)
25. Gardiner TA, Anderson HR, Stitt AW. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol. 2003;201:328-33. (Pubitemid 37258944)
26. Gardiner TA, Archer DB, Curtis TM, et al. Arteriolar involvement in the microvascular lesions of diabetic retinopathy: implications for pathogenesis. Microcirculation. 2007;14:25-38. (Pubitemid 46321703)
27. Genuth S, Sun W, Cleary P, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 2005;54:3103-11. (Pubitemid 43334362)
28. Glomb MA, Pfahler C. Amides are novel protein modifications formed by physiological sugars. J Biol Chem. 2001;276:41638-47.
29. Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597-605. (Pubitemid 44199649)
30. Griesmacher A, Kindhauser M, Andert SE, et al. Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am J Med. 1995;98:469-75.
31. Hamann K, Shi R. Acrolein scavenging: a potential novel mechanism of attenuating oxidative stress following spinal cord injury. J Neurochem. 2009;111:1348-56.
32. Hammes HP, Martin S, Federlin K, et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci (USA). 1991;88:11555-8. (Pubitemid 21916080)
33. Hammes HP, Alt A, Niwa T, et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia. 1999;42:728-36. (Pubitemid 29265591)
34. Hammes HP, Brownlee M, Edelstein D, et al. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 1994;37:32-5. (Pubitemid 24044704)
35. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9:294-9. (Pubitemid 36362784)
36. Hughes SJ, Wall N, Scholfield CN, et al. Advanced glycation endproduct modified basement membrane attenuates endothelin-1 induced [Ca2+]i signalling and contraction in retinal microvascular pericytes. Mol Vis. 2004;10:996-1004. (Pubitemid 41358192)
37. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450-2. (Pubitemid 39561611)
38. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes. 2001;50:1636-42. (Pubitemid 33639605)
39. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun. 1999;257:251-8. (Pubitemid 29301430)
40. Kilhovd BK, Giardino I, Torjesen PA, et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism. 2003;52:163-7. (Pubitemid 36388837)
41. Kislinger T, Fu C, Huber B, et al. N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740-9.
42. Kuhla B, Luth HJ, Haferburg D, et al. Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease. Ann N Y Acad Sci. 2005;1043:211-6. (Pubitemid 41123908)
43. Lecleire-Collet A, Tessier LH, Massin P, et al. Advanced glycation end products can induce glial reaction and neuronal degeneration in retinal explants. Br J Ophthalmol. 2005;89:1631-3. (Pubitemid 41729910)
44. Liu B, Bhat M, Padival AK, et al. Effect of dicarbonyl modification of fibronectin on retinal capillary pericytes. Investig Ophthalmol Vis Sci. 2004;45:1983-95. (Pubitemid 38868998)
45. Losada M, Alio JL. Malondialdehyde serum concentration in type 1 diabetic with and without retinopathy. Doc Ophthalmol. 1996;93:223-9. (Pubitemid 28126126)
46. Mamputu JC, Renier G. Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide. Diabetes Obes Metab. 2004;6:95-103. (Pubitemid 38220101)
47. Miller AG, Smith DG, Bhat M, et al. Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions. J Biol Chem. 2006;281:11864-71. (Pubitemid 43855447)
48. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with longterm intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 1999;48:870-80. (Pubitemid 29153089)
49. Monnier VM, Mustata GT, Biemel KL, et al. Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: an update on "a puzzle nearing resolution". Ann N Y Acad Sci. 2005;1043:533-44. (Pubitemid 41123943)
50. Monnier VM, Sell DR, Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann N Y Acad Sci. 2005;1043:567-81. (Pubitemid 41123947)
51. Moore TC, Moore JE, Kaji Y, et al. The role of advanced glycation end products in retinal microvascular leukostasis. Investig Ophthalmol Vis Sci. 2003;44:4457-64. (Pubitemid 37186283)
52. Morcos M, Du X, Pfisterer F, et al. Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell. 2008;7:260-9. (Pubitemid 351359658)
53. Murata T, Nagai R, Ishibashi T, et al. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 1997;40:764-9. (Pubitemid 27306953)
54. O'Brien PJ, Siraki AG, Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol. 2005;35:609-62. (Pubitemid 41693601)
55. Ono Y, Aoki S, Ohnishi K, et al. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract. 1998;41:131-7. (Pubitemid 28459016)
56. Padayatti PS, Jiang C, Glomb MA, et al. High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells. Curr Eye Res. 2001;23:106-15. (Pubitemid 34499632)
57. Phipps JA, Fletcher EL, Vingrys AJ. Paired-flash identification of rod and cone dysfunction in the diabetic rat. Investig Ophthalmol Vis Sci. 2004;45:4592-600. (Pubitemid 39564688)
58. Ren XY, Li YN, Qi JS, et al. Peroxynitrite-induced protein nitration contributes to liver mitochondrial damage in diabetic rats. J Diabetes Complications. 2008;22:357-64.
59. Roy MS, Gunkel RD, Podgor MJ. Color vision defects in early diabetic retinopathy. Arch Ophthalmol. 1986;104:225-8. (Pubitemid 16119619)
60. Schalkwijk CG, Ligtvoet N, Twaalfhoven H, et al. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes. 1999;48:2446-53. (Pubitemid 30395438)
61. Schlotterer A, Kukudov G, Bozorgmehr F, et al. C. elegans as model for the study of high glucose-mediated life span reduction. Diabetes. 2009;58:2450-6.
62. Shinohara M, Thornalley PJ, Giardino I, et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest. 1998;101:1142-7. (Pubitemid 28125293)
63. Sokol S, Moskowitz A, Skarf B, et al. Contrast sensitivity in diabetics with and without background retinopathy. Arch Ophthalmol. 1985;103:51-4. (Pubitemid 15152624)
64. Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol. 2001;85:746-53. (Pubitemid 32554256)
65. Stitt AW, Gardiner TA, Alderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002;51:2826-32. (Pubitemid 34970937)
66. Stitt AW, Li YM, Gardiner TA, et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol. 1997;150:523-31. (Pubitemid 27073782)
67. Stitt AW, Mcgoldrick C, Rice-Mccaldin A, et al. Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes. 2005;54:785-94. (Pubitemid 40322083)
68. Stitt AW, Moore JE, Sharkey JA, et al. Advanced glycation end products in vitreous: structural and functional implications for diabetic vitreopathy. Investig Ophthalmol Vis Sci. 1998;39:2517-23. (Pubitemid 28558209)
69. Sugiyama S, Miyata T, Ueda Y, et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol. 1998;9:1681-8.
70. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev. 2005;1:287-98.
71. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J. 1999;344(Pt 1):109-16.
72. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids. 2003; 25:275-81. (Pubitemid 38041265)
73. Tomitori H, Usui T, Saeki N, et al. Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. Stroke. 2005;36:2609-13.
74. Toyokuni S, Yamada S, Kashima M, et al. Serum 4-hydroxy-2-nonenal- modified albumin is elevated in patients with type 2 diabetes mellitus. Antioxid Redox Signal. 2000;2:681-5. (Pubitemid 32062319)
75. Uchida K, Kanematsu M, Morimitsu Y, et al. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem. 1998;273:16058-66. (Pubitemid 28311374)
76. Voziyan PA, Metz TO, Baynes JW, et al. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem. 2002;277:3397-403. (Pubitemid 34953208)
77. Wagner Z, Wittmann I, Mazak I, et al. N(epsilon)-(carboxymethyl) lysine levels in patients with type 2 diabetes: role of renal function. Am J Kidney Dis. 2001;38:785-91.
78. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53. (Pubitemid 38579764)
79. Xu X, Li Z, Luo D, et al. Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2003;241:56-62. (Pubitemid 36747788)
80. Yamagishi S, Fujimori H, Yonekura H, et al. Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem Biophys Res Commun. 1999;258:353-7. (Pubitemid 29287055)
81. Yamaguchi M, Nakamura N, Nakano K, et al. Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy. Diabet Med. 1998;15:458-62. (Pubitemid 28261141)
82. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996;382:685-91. (Pubitemid 26282167)
83. Yao D, Taguchi T, Matsumura T, et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem. 2007;282:31038-45. (Pubitemid 350035169)
84. Yonemura D, Aoki T, Tsuzuki K. Electroretinogram in diabetic retinopathy. Arch Ophthalmol. 1962;68:19-24.
85. Yong PH, Zong H, Medina RJ, et al. Evidence supporting a role for N-(3-formyl-3,4-dehydropiperidino)lysine accumulation in Muller glia dysfunction and death in diabetic retinopathy. Mol Vis. 2010;16:2524-38.
86. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126:227-32. (Pubitemid 351240852)
87. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci. 2000;17:463-71.
88. Zhang X, Lai Y, Mccance DR, et al. Evaluation of N (epsilon)-(3-formyl-3, 4-dehydropiperidino)lysine as a novel biomarker for the severity of diabetic retinopathy. Diabetologia. 2008;51:1723-30.
89. Zong H, Ward M, Madden A, et al. Hyperglycaemia-induced proinflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia. 2010;53:2656-66.
90. Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW, Vasiliou V. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics. 2011;5(4):283-303.
91. Berner AK, Brouwers O, Pringle R, Klaassen I, Colhoun L, McVicar C, Brockbank S, Curry JW, Miyata T, Brownlee M, Schlingemann RO, Schalkwijk C, Stitt AW. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia. 2011, doi:10.1007/s00125-011-2393-0.